Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2,260

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)

Open access
Swedberg, Karl, Cleland, John, Dargie, Henry, Drexler, Helmut, Follath, Ferenc, Komajda, Michel, Tavazzi, Luigi, Smiseth, Otto A., Gavazzi, Antonello, Haverich, Axel, Hoes, Arno, Jaarsma, Tiny, Korewicki, Jerzy, Lévy, Samuel, Linde, Cecilia, Lopez-Sendon, José-Luis, Nieminen, Markku S., Piérard, Luc, Remme, Willem J.·2005·European Heart Journal
DOI 10.1093/eurheartj/ehi204
Open this paper in CoChat — free account

Abstract

ESC Committee for Practice Guidelines (CPG), Silvia G. Priori (Chairperson) (Italy), Jean-Jacques Blanc (France), Andrzej Budaj (Poland), John Camm (UK), Veronica Dean (France), Jaap Deckers (The Netherlands), Kenneth Dickstein (Norway), John Lekakis (Greece), Keith McGregor (France), Marco Metra (Italy), João Morais (Portugal), Ady Osterspey (Germany), Juan Tamargo (Spain), José Luis Zamorano (Spain) Document Reviewers, Marco Metra (CPG Review Coordinator) (Italy), Michael Böhm (Germany), Alain Cohen-Solal (France), Martin Cowie (UK), Ulf Dahlström (Sweden), Kenneth Dickstein (Norway), Gerasimos S. Filippatos (Greece), Edoardo Gronda (Italy), Richard Hobbs (UK), John K. Kjekshus (Norway), John McMurray (UK), Lars Rydén (Sweden), Gianfranco Sinagra (Italy), Juan Tamargo (Spain), Michal Tendera (Poland), Dirk van Veldhuisen (The Netherlands), Faiez Zannad (France) Guidelines and Expert Consensus Documents aim to present all the relevant evidence on a particular issue in order to help physicians to weigh the benefits and risks of a particular diagnostic or therapeutic procedure. They should be helpful in everyday clinical decision-making. A great number of Guidelines and Expert Consensus Documents have been issued in recent years by the European Society of Cardiology (ESC) and by different organizations and other related societies. This profusion can put at stake the authority and validity of guidelines, which can only be guaranteed if they have been developed by an unquestionable decision-making process. This is one of the reasons why the ESC and others have issued recommendations for formulating and issuing Guidelines and Expert Consensus Documents. In spite of the fact that standards for issuing good quality Guidelines and Expert Consensus Documents are well defined, recent surveys of Guidelines and Expert Consensus Documents published in peer-reviewed journals between 1985 and 1998 have shown that methodological standards were not complied with in the vast majority of cases. It is therefore of great importance that guidelines and recommendations are presented in formats that are easily interpreted. Subsequently, their implementation programmes must also be well conducted. Attempts have been made to determine whether guidelines improve the quality of clinical practice and the utilization of health resources. The ESC Committee for Practice Guidelines (CPG) supervises and coordinates the preparation of new Guidelines and Expert Consensus Documents produced by Task Forces, expert groups, or consensus panels. The chosen experts in these writing panels are asked to provide disclosure statements of all relationships they may have which might be perceived as real or potential conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. The Committee is also responsible for the endorsement of these Guidelines and Expert Consensus Documents or statements. The Task Force has classified and ranked the usefulness or efficacy of the recommended procedure and/or treatments and the Level of Evidence as indicated in the tables on page 3. These Guidelines are based on the Diagnostic and Therapeutic Guidelines published in 1995, 1997, and renewed in 2001,1–3 which has now been combined into one manuscript. Where new information is available, an update has been performed while other parts are unchanged or adjusted only to a limited extent. The aim of this report is to provide updated practical guidelines for the diagnosis, assessment, and treatment of heart failure for use in clinical practice, as well as for epidemiological surveys and clinical trials. Particular attention in this update has been allocated to diastolic function and heart failure with preserved left ventricular ejection fraction (PLVEF). The intention has been to merge the previous Task Force report4 with the present update. The Guidelines are intended as a support for practising physicians and other health care professionals concerned with the management of heart failure patients and to provide advice on how to manage these patients, including recommendations for referral. Documented and published evidence on diagnosis, efficacy, and safety is the main basis for these guidelines. ESC Guidelines are relevant to 49 member-states with diverse economies and therefore recommendations based on cost-effectiveness have been avoided in general. National health policy as well as clinical judgement may dictate the order of priority of implementation. It is recognized that some interventions may not be affordable in some countries for all appropriate patients. The recommendations in these guidelines should therefore always be considered in the light of national policies and local regulatory requirements for the administration of any diagnostic procedure, medicine, or device. This report was drafted by a Writing Group of the Task Force (see title page) appointed by the CPG of the ESC. Within this Task Force, s

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehi204

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 140

  1. The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J1995;16:741–751.
  2. The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J1997;18:736–753. · DOI · Paper page
  3. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J2001;22:1527–1560. · DOI · Paper page
  4. How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J1998;19:990–1003. · DOI · Paper page
  5. Mosterd A, Hoes AW, de Bruyne MC et al. Prevalence of heart failure and left ventricular dysfunction in the general population. Eur Heart J1999;20:447–455. · DOI · Paper page
  6. McDonagh TA, Morrison CE, Lawrence A et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet1997;350:829–833. · DOI · Paper page
  7. Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it? Eur Heart J2001;22:623–626. · DOI · Paper page
  8. McMurray J, McDonagh T, Morrison CE et al. Trends in hospitalization for heart failure in Scotland 1980–1990. Eur Heart J1993;14:1158–1162. · DOI · Paper page
  9. Cleland JG, Gemmell I, Khand A et al. Is the prognosis of heart failure improving? Eur J Heart Fail1999;1:229–241. · DOI
  10. Cleland JG, Swedberg K, Follath F et al. The Euro Heart Failure Survey Programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J2003;24:442–463. · DOI · Paper page
  11. Wheeldon NM, MacDonald TM, Flucker CJ et al. Echocardiography in chronic heart failure in the community. Q J Med1993;86:17–23. · DOI · Paper page
  12. Remes J, Miettinen H, Reunanen A et al. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J1991;12:315–321. · DOI · Paper page
  13. Task Force on Acute Heart Failure. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J2005;26:384–416. · DOI · Paper page
  14. McMurray J, Swedberg K, Hogg K. Heart failure with preserved left ventricular systolic function. J Am Coll Cardiol2004;43:317–327. · DOI · Paper page
  15. Braunwald E. Heart failure: an overview. In: Fishma AP, ed. Heart Failure. New York: McGraw-Hill; 1977.
  16. Denolin H, Kuhn H, Krayenbuehl HP et al. The definition of heart failure. Eur Heart J1983;4:445–448. · DOI
  17. Lipkin DP, Canepa-Anson R, Stephens MR et al. Factors determining symptoms in heart failure: comparison of fast and slow exercise tests. Br Heart J1986;55:439–445. · DOI
  18. Puri S, Baker BL, Oakley CM et al. Increased alveolar/capillary membrane resistance to gas transfer in patients with chronic heart failure. Br Heart J1994;72:140–144. · DOI
  19. Butman SM, Ewy GA, Standen JR et al. Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension. J Am Coll Cardiol1993;22:968–974. · DOI · Paper page
  20. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA1989;10:884–888. · DOI · Paper page
  21. Marantz PR TJW-SSS, Budner N, Lense L et al. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation1988;77:607–612. · DOI · Paper page
  22. Adams KF, Zannad F. Clinical definition and epidemiology of advanced heart failure. Am Heart J1998;135:S204–S215. · DOI
  23. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol1967;20:457–464. · DOI · Paper page
  24. Khot UN, Jia G, Moliterno DJ et al. Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. JAMA2003;290:2174–2181. · DOI · Paper page
  25. McMurray J, Ostergren J, Pfeffer M et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail2003;5:261–270. · DOI
  26. Luchner A, Burnett JC, Jougasaki M et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens2000;18:1121–1128. · DOI
  27. Clerico A, Del Ry S, Maffei S et al. The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med2002;40:371–377. · DOI
  28. Tsutamoto T, Wada A, Maeda K et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation1997;96:509–516. · DOI · Paper page
  29. Krüger S, Graf J, Merx MW et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J2004;147:60–65. · DOI
  30. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med2002;347:161–167. · DOI · Paper page
  31. Working Group Report. How to diagnose diastolic heart failure? European Study Group on Diastolic Heart Failure. Eur Heart J1998;19:990–1003. · DOI · Paper page
  32. Caruana L, Petrie MC, Davie AP et al. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from “diastolic heart failure” or from misdiagnosis? A prospective descriptive study. BMJ2000;321:215–218. · DOI · Paper page
  33. Thomas JD, Choong CY, Flachskampf FA et al. Analysis of the early transmitral Doppler velocity curve: effect of primary physiologic changes and compensatory preload adjustment. J Am Coll Cardiol1990;16:644–655. · DOI
  34. Sohn DW, Chai IH, Lee DJ et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol1997;30:474–480. · DOI · Paper page
  35. Bellenger NG, Davies LC, Francis JM et al. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson2000;2:271–278. · DOI · Paper page
  36. Grothues F, Moon JC, Bellenger NG et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J2004;147:218–223. · DOI · Paper page
  37. Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet1997;349:1050–1053. · DOI · Paper page
  38. Working Group on Cardiac Rehabilitation and Exercise Physiology and Working group on Heart Failure of the European Society of Cardiology. Recommendations for exercise testing in chronic heart failure patients. Eur Heart J2001;22:37–45.
  39. Kober L, Torp-Pedersen C, Carlsen JE et al. Effects on mortality by trandolapril after myocardial infarction. N Engl J Med1995;333:1670–1676. · DOI · Paper page
  40. Jong P, Yusuf S, Rousseau MF et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet2003;361:1843–1848. · DOI · Paper page
  41. Flather M, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet2000;355:1575–1581. · DOI · Paper page
  42. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med1987;316:1429–1435. · DOI
  43. The acute infarction ramipril efficacy. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet1993;342:821–828. · DOI · Paper page
  44. Kaddoura S, Patel D, Parameshwar J et al. Objective assessment of the response to treatment of severe heart failure using a 9-minute walk test on a patient-powered treadmill. J Card Fail1996;2:133–139. · DOI
  45. Bayliss J, Norell M, Canepa-Anson R et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J1987;57:17–22. · DOI · Paper page
  46. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med1996;334:1349–1355. · DOI · Paper page
  47. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet1997;349:375–380. · DOI · Paper page
  48. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet1999;353:9–13. · DOI · Paper page
  49. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet1999;353:2001–2007. · DOI
  50. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. Circulation2000;101:378–384. · DOI
  51. Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J2005;26:215–225. · DOI
  52. The Capricorn Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet2001;357:1385–1390. · DOI · Paper page
  53. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med2001;344:1659–1667. · DOI · Paper page
  54. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet2003;362:7–13. · DOI · Paper page
  55. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet2003;362:772–776. · DOI · Paper page
  56. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet2003;362:759–766. · DOI · Paper page
  57. Jong P, Demers C, McKelvie RS et al. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol2002;39:463–470. · DOI
  58. Coletta AP, Cleland JG, Freemantle N et al. Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. Eur J Heart Fail2003;5:697–704. · DOI
  59. Khand AU, Rankin AC, Kaye GC et al. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J2000;21:614–632. · DOI
  60. Khand AU, Rankin AC, Martin W et al. Digoxin or carvedilol for the treatment of atrial fibrillation in patients with heart failure? (Abstract). Heart2000;83:30.
  61. Cohn JN, Ziesche S, Smith R et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation1997;96:856–863. · DOI · Paper page
  62. Thackray S, Witte K, Clark AL et al. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail2000;2:209–212. · DOI
  63. Follath F, Cleland JG, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet2002;360:196–202. · DOI · Paper page
  64. Cleland JG, Cowburn PJ, Falk RH. Should all patients with atrial fibrillation receive warfarin? Evidence from randomized clinical trials. Eur Heart J1996;17:674–681. · DOI
  65. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ2002;324:71–86. · DOI · Paper page
  66. Cleland JG, Findlay I, Jafri S et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J2004;148:157–164. · DOI · Paper page
  67. Teo KK, Yusuf S, Pfeffer M et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet2002;360:1037–1043. · DOI
  68. Cleland JG, Ghosh J, Freemantle N et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail2004;6:501–508. · DOI
  69. The Cardiac Arrhythmia Suppression Trial. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med1989;321:406–412. · DOI · Paper page
  70. Steinbeck G, Andresen D, Bach P et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med1992;327:987–992. · DOI
  71. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet1997;350:1417–1424. · DOI · Paper page
  72. Levy S, Breithardt G, Campbell RW et al. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J1998;19:1294–1320. · DOI · Paper page
  73. Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med1995;333:77–82. · DOI · Paper page
  74. Linde C, Leclercq C, Rex S et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol2002;40:111–118. · DOI · Paper page
  75. Bradley DJ, Bradley EA, Baughman KL et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA2003;289:730–740. · DOI · Paper page
  76. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med2002;346:877–883. · DOI · Paper page
  77. Kadish A, Dyer A, Daubert JP et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med2004;350:2151–2158. · DOI · Paper page
  78. Jauhar S, Slotwiner DJ. The economics of ICDs. N Engl J Med2004;351:2542–2544. · DOI
  79. Nanthakumar K, Epstein AE, Kay GN et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction. A pooled analysis of 10 primary prevention trials. J Am Coll Cardiol2004;44:2166–2172. · DOI
  80. Desai AS, Fang JC, Maisel WH et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA2004;292:2874–2879. · DOI · Paper page
  81. Salukhe TV, Dimopoulos K, Sutton R et al. Life-years gained from defibrillator implantation: markedly nonlinear increase during 3 years of follow-up and its implications. Circulation2004;109:1848–1853. · DOI
  82. Rose EA, Gelijns AC, Moskowitz AJ et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med2001;345:1435–1443. · DOI · Paper page
  83. Rimondini A, Cipolla CM, Della Bella P et al. Hemofiltration as short-term treatment for refractory congestive heart failure. Am J Med1987;83:43–48. · DOI
  84. Dormans TP, Huige RM, Gerlag PG. Chronic intermittent haemofiltration and haemodialysis in end stage chronic heart failure with oedema refractory to high dose frusemide. Heart1996;75:349–351. · DOI
  85. Fuster V, Rydén LE, Asinger RW et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation2001;104:2118–2150.
  86. Setaro JF, Zaret BL, Schulman DS et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol1990;66:981–986. · DOI · Paper page
  87. Bonow RO, Dilsizian V, Rosing DR et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation1985;72:853–864. · DOI · Paper page
  88. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362:777–781. · DOI · Paper page
  89. The antiarrhythmics versus implantable defibrillators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med1997;337:1576–1583. · DOI · Paper page
  90. Priori SG, Aliot E, Blomstrom-Lundqvist C et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J2001;22:1374–1450. · DOI · Paper page
  91. Torp-Pedersen C, Moller M, Bloch-Thomsen PE et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med1999;341:857–865. · DOI · Paper page
  92. Rich MW. Heart failure disease management: a critical review. J Card Fail1999;5:64–75. · DOI
  93. McAlister FA, Lawson FM, Teo KK et al. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ2001;323:957–962. · DOI · Paper page
  94. Stewart S, Pearson S, Horowitz JD. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med1998;158:1067–1072. · DOI · Paper page
  95. Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet1999;354:1077–1083. · DOI · Paper page
  96. Stromberg A. Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure: results from a prospective, randomised trial. Eur Heart J2003;24:1014–1023. · DOI · Paper page
  97. Weinberger M, Oddone EZ, Henderson WG. Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med1996;334:1441–1447. · DOI · Paper page
  98. Jaarsma T, Halfens R, Huijer Abu-Saad H et al. Effects of education and support on self-care and resource utilization in patients with heart failure. Eur Heart J1999;20:673–682. · DOI · Paper page
  99. Ekman I, Andersson B, Ehnfors M et al. Feasibility of a nurse-monitored, outpatient-care programme for elderly patients with moderate-to-severe, chronic heart failure. Eur Heart J1998;19:1254–1260. · DOI
  100. McAlister FA, Stewart S, Ferrua S et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol2004;44:810–819. · DOI
  101. Nohria A, Tsang SW, Fang JC et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol2003;41:1797–1804. · DOI · Paper page
  102. Kearney MT, Fox KA, Lee AJ et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol2002;40:1801–1808. · DOI
  103. Pulignano G, Del Sindaco D, Tavazzi L et al. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J2002;143:45–55. · DOI
  104. Yancy CW. Does race matter in heart failure? Am Heart J2003;146:203–206. · DOI
  105. Baldasseroni S, Opasich C, Gorini M et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J2002;143:398–405. · DOI · Paper page
  106. Mancini DM, Eisen H, Kussmaul W et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation1991;83:778–786. · DOI · Paper page
  107. Recommendations for exercise testing in chronic heart failure patients. Eur Heart J2001;22:37–45. · DOI
  108. Opasich C, Pinna GD, Bobbio M et al. Peak exercise oxygen consumption in chronic heart failure: toward efficient use in the individual patient. J Am Coll Cardiol1998;31:766–775. · DOI
  109. Vrtovec B, Delgado R, Zewail A et al. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation2003;107:1764–1769. · DOI
  110. Lewis EF, Moye LA, Rouleau JL et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol2003;42:1446–1453. · DOI · Paper page
  111. Hohnloser SH, Klingenheben T, Bloomfield D et al. Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study. J Am Coll Cardiol2003;41:2220–2224. · DOI
  112. Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol2002;39:210–218. · DOI
  113. Corra U, Mezzani A, Bosimini E et al. Ventilatory response to exercise improves risk stratification in patients with chronic heart failure and intermediate functional capacity. Am Heart J2002;143:418–426. · DOI
  114. Swedberg K, Eneroth P, Kjekshus J et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation1990;82:1730–1736. · DOI · Paper page
  115. St John SM, Lee D, Rouleau JL et al. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation2003;107:2577–2582. · DOI
  116. Koelling TM, Aaronson KD, Cody RJ et al. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J2002;144:524–529. · DOI
  117. Gustafsson F, Torp-Pedersen C, Brendorp B et al. Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur Heart J2003;24:863–870. · DOI
  118. Bittner V, Weiner DH, Yusuf S et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA1993;270:1702–1707. · DOI · Paper page
  119. Opasich C, Pinna GD, Mazza A et al. Reproducibility of the six-minute walking test in patients with chronic congestive heart failure: practical implications. Am J Cardiol1998;81:1497–1500. · DOI
  120. Gronda E, Mangiavacchi M, Frigerio M et al. Determination of candidacy for mechanical circulatory support: importance of clinical indices. J Heart Lung Transplant2000;19:S83–S88. · DOI
  121. Anker SD, Negassa A, Coats AJ et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet2003;361:1077–1083. · DOI · Paper page
  122. Aaronson KD, Schwartz JS, Chen TM et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation1997;95:2660–2667. · DOI · Paper page
  123. Dries DL, Exner DV, Domanski MJ et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol2000;35:681–689. · DOI · Paper page
  124. Ponikowski P, Francis DP, Piepoli MF et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation2001;103:967–972. · DOI · Paper page
  125. Leite JJ, Mansur AJ, de Freitas HF et al. Periodic breathing during incremental exercise predicts mortality in patients with chronic heart failure evaluated for cardiac transplantation. J Am Coll Cardiol2003;41:2175–2181. · DOI
  126. Pozzoli M, Traversi E, Cioffi G et al. Loading manipulations improve the prognostic value of Doppler evaluation of mitral flow in patients with chronic heart failure. Circulation1997;95:1222–1230. · DOI
  127. Pinamonti B, Zecchin M, Di Lenarda A et al. Persistence of restrictive left ventricular filling pattern in dilated cardiomyopathy: an ominous prognostic sign. J Am Coll Cardiol1997;29:604–612. · DOI
  128. Ghio S, Gavazzi A, Campana C et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol2001;37:183–188. · DOI · Paper page
  129. Polak JF, Holman BL, Wynne J et al. Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol1983;2:217–224. · DOI
  130. Ammann P, Maggiorini M, Bertel O et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol2003;41:2004–2009. · DOI · Paper page
  131. Petrie MC, McMurray JV. It cannot be cardiac failure because the heart is not enlarged on the chest X-ray. Eur J Heart Fail2003;5:117–119. · DOI
  132. Anker SD, Doehner W, Rauchhaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation2003;107:1991–1997. · DOI · Paper page
  133. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet1999;353:9–13. · DOI · Paper page
  134. Murdoch DR, McDonagh TA, Farmer R et al. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE-inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J2001;141:800–807. · DOI
  135. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet2000;355:1582–1587. · DOI · Paper page
  136. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002;359:995–1003. · DOI · Paper page
  137. Tonkon M. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE-inhibitors, in heart failure. Irbesartan Heart Failure Group. Int J Clin Pract2000;54:11–14. · DOI
  138. Dunselman PH. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. Int J Cardiol2001;77:131–138. · DOI
  139. McMurray JJ, Ostergren J, Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet2003;362:767–771. · DOI · Paper page
  140. Cleland JG, Daubert JC, Erdmann E. et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med2005;352:1539–1549. · DOI · Paper page

Cited by

See all 2,260

Metadata

Authors
Swedberg, K., Cleland, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., Tavazzi, L., Smiseth, O. A., Gavazzi, A., Haverich, A., Hoes, A., Jaarsma, T., Korewicki, J., Lévy, S., Linde, C., Lopez-Sendon, J.-L., Nieminen, M. S., Piérard, L., & Remme, W. J.
Venue
European Heart Journal
Publisher
Oxford University Press (OUP)
Published
2005-05-18
Volume
26
Issue
11
Pages
1115-1140
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
DOI
10.1093/eurheartj/ehi204
OpenAlex
W2137412139
Cited by
2,260
References
26
FWCI
219.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). https://app.cochat.ai/papers/10.1093/eurheartj/ehi204
The paper
Swedberg, K., Cleland, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., Tavazzi, L., Smiseth, O. A., Gavazzi, A., Haverich, A., Hoes, A., Jaarsma, T., Korewicki, J., Lévy, S., Linde, C., Lopez-Sendon, J.-L., Nieminen, M. S., Piérard, L., & Remme, W. J. (2005). Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). European Heart Journal. https://doi.org/10.1093/eurheartj/ehi204

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.